ALMS
ALUMIS INC.
NASDAQ · Healthcare · Biotechnology · US
$6.34
+3.59%Oct 9, 2026, 08:00 UTC
Alumis announced new Phase 3 clinical data for envudeucitinib from the ONWARD1, ONWARD2 and ONWARD3 programs, reporting improvements in psoriasis burden across scalp, itch and quality-of-life measures.
Source:Sep 1, 2026, 13:03 UTC
ALUMIS stock resumed trading and plunged 57% in premarket after a failed trial sale.
Sep 1, 2026, 11:30 UTC
Alumis announced that its Phase 2b LUMUS trial of envudeucitinib for systemic lupus erythematosus did not meet primary and secondary endpoints in the overall population, but showed robust responses in the IFNGS-high subgroup, supporting Phase 3 development in SLE.
Source:Aug 10, 2026, 21:45 UTC
Alumis announced topline results from its ONWARD3 long-term extension study, showing envudeucitinib achieved high skin clearance rates in psoriasis patients.